The Neurotechnology Innovations Translator attracts and develops neurotechnology projects
from around the globe, propelling them from concept-to-clinic by providing comprehensive
resources, expertise, capital and a progressive development model.
The Neurotechnology Innovations Translator (NIT) is a cutting-edge translational
center in Columbus—a private entity formed in collaboration with The Ohio State
University and more than a dozen private, public, government and industry partners
from across Ohio and the U.S. NIT’s mission is to attract, develop and commercialize
pioneering neurotechnology solutions to improve patients’ lives and well-being. In
collaboration with its partners, NIT holds total capital and service commitments of
more than $160 million, bringing together the infrastructure, support and solutions
to accelerate a company’s development cycle, thereby compressing time, risk and
NIT started with a simple question: “How can neurotechnology companies continue
to pioneer innovations in today’s academic and medical technology environment?”
The result: the NIT Translational approach, highly unique, not just in neurotechnology,
but across the field of medtech development. This approach systematically facilitates
a company’s rapid development throughout the development pathway. NIT’s
ecosystem of partners contributes broad, cross-functional capabilities to accelerate
and shepherd development, virtually all the development resources necessary for
neurotechnology company translation, with many directly onsite or within short
walking distance. In concert, NIT delivers dedicated investment funds to capitalize and propel companies forward in each
development and investment stage, whether “seeding” a new idea, leading an investment round or joining an investment group.
Collectively, NIT brings together the vision, leadership, expertise, network, resources, personnel and capital to create the pre-eminent development ecosystem for neurotechnologies—a comprehensive solution to catapult projects from concept-to-clinic.
Whether an idea on a napkin, a dream and passion of a clinician or researcher to improve lives or a more mature and established
company that is further along in the development pathway, the NIT will develop a select number of high-quality, neurotechnology
innovations, spanning therapeutics to diagnostics and monitoring and preventive and therapeutic solutions.
Creating Compelling Solutions to Improve
Patients’ Lives Through Innovation and
Kevin Wasserstein, MBA, CEO